Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | ABCB1 | P08183 | 15/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | SLC43A1 | O75387 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29324933 | 0.95 | ALDH1A1 (0.45) | ALDH1A1ABCB1NPC1TSHRSLC43A1 | |
| SCHEMBL12111919 | 0.88 | ALDH1A1 (0.44) | ALDH1A1ABCB1NPC1TSHRSLC43A1 | |
| SCHEMBL12112020 | 0.88 | ALDH1A1 (0.44) | ALDH1A1ABCB1NPC1TSHRSLC43A1 | |
| SCHEMBL14724959 | 0.87 | ALDH1A1 (0.48) | ALDH1A1ABCB1NPC1TSHR | |
| SCHEMBL10148068 | 0.86 | ALDH1A1 (0.43) | ALDH1A1ABCB1NPC1TSHR | |
| SCHEMBL4284935 | 0.86 | ALDH1A1 (0.43) | ALDH1A1ABCB1NPC1 | |
| SCHEMBL10147725 | 0.86 | ALDH1A1 (0.43) | ALDH1A1ABCB1NPC1TSHR | |
| SCHEMBL20557502 | 0.84 | ALDH1A1 (0.45) | ALDH1A1ABCB1NPC1TSHR | |
| SCHEMBL16576324 | 0.84 | ALDH1A1 (0.45) | ALDH1A1ABCB1NPC1TSHR | |
| SCHEMBL27087661 | 0.84 | ALDH1A1 (0.45) | ALDH1A1ABCB1NPC1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8883758-B2 | 3,5-disubstituted and 3,5,7-trisubstituted-3H-oxazolo and 3H-thiazolo[4,5-d]pyrimidin-2-one compounds and prodrugs thereof | ANADYS PHARMACEUTICALS, INC. (US) | 2014-11-11 | — | — | US | disclosed |
| US-20130259831-A1 | 3,5-Disubstituted and 3,5,7-Trisubstituted-3H-Oxazolo and 3H-Thiazolo[4,5-d]pyrimidin-2-one Compounds and Prodrugs Thereof | ANADYS PHARMACEUTICALS, INC. (US) | 2013-10-03 | — | — | US | disclosed |
| US-20120121541-A1 | 3,5-DISUBSTITUTED AND 3,5,7-TRISUBSTITUTED-3H-OXAZOLO AND 3H-THIAZOLO[4,5-D]PYRIMIDIN-2-ONE COMPOUNDS AND PRODRUGS THEREOF | ANADYS PHARMACEUTICALS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20110275589-A1 | 3,5-DISUBSTITUTED AND 3,5,7-TRISUBSTITUTED-3H-OXAZOLO AND 3H-THIAZOLO[4,5-d]PYRIMIDIN-2-ONE COMPOUNDS AND PRODRUGS THEREOF | ANADYS PHARMACEUTICALS, INC. (US) | 2011-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130259831-A1 | 3,5-Disubstituted and 3,5,7-Trisubstituted-3H-Oxazolo and 3H-Thiazolo[4,5-d]pyrimidin-2-one Compounds and Prodrugs Thereof | TLR5, THPO, IDO1 | ALDH1A1 340/4885ABCB1 381/4885NPC1 1441/4885 |
| US-20110275589-A1 | 3,5-DISUBSTITUTED AND 3,5,7-TRISUBSTITUTED-3H-OXAZOLO AND 3H-THIAZOLO[4,5-d]PYRIMIDIN-2-ONE COMPOUNDS AND PRODRUGS THEREOF | TLR5, THPO, IDO1 | ALDH1A1 340/4885ABCB1 381/4885NPC1 1441/4885 |
| US-20120121541-A1 | 3,5-DISUBSTITUTED AND 3,5,7-TRISUBSTITUTED-3H-OXAZOLO AND 3H-THIAZOLO[4,5-D]PYRIMIDIN-2-ONE COMPOUNDS AND PRODRUGS THEREOF | TLR5, THPO, IDO1 | ALDH1A1 340/4885ABCB1 381/4885NPC1 1441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.